LT3484865T - Somatostatino moduliatoriai ir jų panaudojimas - Google Patents

Somatostatino moduliatoriai ir jų panaudojimas

Info

Publication number: LT3484865T
Authority: LT; Lithuania
Prior art keywords: somatostatin modulators; somatostatin; modulators
Prior art date: 2016-07-14

Application number

LTEPPCT/US2017/041694T

Other languages

English (en)

Inventor

Jian Zhao

Sangdon Han

Sun Hee Kim

Shimiao Wang

Yunfei Zhu

Original Assignee

Crinetics Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-14

Filing date

2017-07-12

Publication date

2022-11-10

2017-07-12 Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.

2022-11-10 Publication of LT3484865T publication Critical patent/LT3484865T/lt

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)

LTEPPCT/US2017/041694T 2016-07-14 2017-07-12 Somatostatino moduliatoriai ir jų panaudojimas LT3484865T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662362493P	2016-07-14	2016-07-14
US201662411338P	2016-10-21	2016-10-21
PCT/US2017/041694 WO2018013676A1 (en)	2016-07-14	2017-07-12	Somatostatin modulators and uses thereof

Publications (1)

Publication Number	Publication Date
LT3484865T true LT3484865T (lt)	2022-11-10

Family

ID=60941935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2017/041694T LT3484865T (lt)	2016-07-14	2017-07-12	Somatostatino moduliatoriai ir jų panaudojimas

Country Status (24)

Country	Link
US (7)	US9896432B2 (lt)
EP (2)	EP4163276A1 (lt)
JP (2)	JP6967577B2 (lt)
KR (2)	KR20210134838A (lt)
CN (2)	CN115557929A (lt)
AU (2)	AU2017296392B2 (lt)
CA (1)	CA3030423A1 (lt)
DK (1)	DK3484865T3 (lt)
ES (1)	ES2931472T3 (lt)
HR (1)	HRP20221279T1 (lt)
HU (1)	HUE060182T2 (lt)
IL (1)	IL264178B2 (lt)
LT (1)	LT3484865T (lt)
MX (1)	MX390120B (lt)
NZ (1)	NZ750174A (lt)
PL (1)	PL3484865T3 (lt)
PT (1)	PT3484865T (lt)
RS (1)	RS63776B1 (lt)
SG (1)	SG11201900349VA (lt)
SM (1)	SMT202200465T1 (lt)
TW (1)	TWI789355B (lt)
UA (1)	UA125393C2 (lt)
WO (1)	WO2018013676A1 (lt)
ZA (1)	ZA201900317B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL264178B2 (en) *	2016-07-14	2024-05-01	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
EP3596062A4 (en)	2017-03-16	2020-08-26	Crinetics Pharmaceuticals, Inc.	SOMATOSTATIN MODULATORS AND THEIR USES
EP3658560A4 (en)	2017-07-25	2021-01-06	Crinetics Pharmaceuticals, Inc.	SOMATOSTAT IN MODULATORS AND USES THEREOF
PT3740475T (pt)	2018-01-17	2022-07-18	Crinetics Pharmaceuticals Inc	Processo de produção de moduladores da somatostatina
MA51840A (fr) *	2018-02-12	2021-05-19	Crinetics Pharmaceuticals Inc	Modulateurs de somatostatine et leurs utilisations
EP3807248A4 (en) *	2018-05-29	2021-10-27	Council of Scientific and Industrial Research	BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
SMT202500155T1 (it)	2018-09-18	2025-05-12	Crinetics Pharmaceuticals Inc	Modulatori della somatostatina e loro usi
JP2022540922A (ja) *	2019-07-17	2022-09-20	クリネティックスファーマシューティカルズ，インク．	ソマトスタチンモジュレーターの結晶形態
TWI841768B (zh) *	2019-08-14	2024-05-11	美商克林提克斯醫藥股份有限公司	非肽生長抑制素(somatostatin)5型受體激動劑及其用途
CA3191084A1 (en) *	2020-09-09	2022-03-17	Gerald Burke	Formulations of a somatostatin modulator
JP2024506715A (ja)	2021-02-17	2024-02-14	クリネティックスファーマシューティカルズ，インク．	ソマトスタチンモジュレーターの結晶形態
BR112023024465A2 (pt) *	2021-05-25	2024-02-06	Crinetics Pharmaceuticals Inc	Usos de um modulador de somatostatina para o tratamento de doença
JP7784437B2 (ja)	2021-09-28	2025-12-11	デンカ株式会社	クロロプレン系ブロック共重合体、ラテックス、ラテックス組成物、及びゴム組成物
WO2023137018A1 (en) *	2022-01-11	2023-07-20	Crinetics Pharmaceuticals, Inc.	Uses of a somatostatin modulator for the treatment of carcinoid syndrome
EP4547654A1 (en)	2022-06-10	2025-05-07	Assia Chemical Industries Ltd.	Solid state forms of paltusotine and process for preparation thereof
IL320483A (en) *	2022-10-28	2025-06-01	Basecamp Bio Inc	Somatostatin receptor 2 agonists and uses thereof
TW202440164A (zh)	2022-12-13	2024-10-16	美商克林提克斯醫藥股份有限公司	生長抑素亞型-2受體（sst2r）靶向治療劑及其用途
KR20250162795A (ko)	2023-03-28	2025-11-19	크리네틱스 파마슈티칼스, 인크.	간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법
WO2025111318A1 (en) *	2023-11-22	2025-05-30	Crinetics Pharmaceuticals, Inc.	Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1035154A (en)	1910-05-16	1912-08-13	Ernest G Clark	Machine for rectifying perforated music and masters.
FR2802206B1 (fr)	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
CA2468159A1 (en)	2001-11-27	2003-06-05	Merck & Co., Inc.	4-aminoquinoline compounds
WO2003066055A1 (en) *	2002-02-04	2003-08-14	F. Hoffmann-La Roche Ag	Quinoline derivatives as npy antagonists
US7767817B2 (en)	2003-09-05	2010-08-03	Binghe Wang	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) *	2004-07-13	2008-03-06	グラクソ　グループ　リミテッド	抗細菌剤
US20060183763A1 (en)	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
US7563821B2 (en)	2005-12-05	2009-07-21	Xenoport, Inc.	Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007098214A1 (en)	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en)	2006-03-08	2007-09-13	Amgen Inc.	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007309708A1 (en) *	2006-03-13	2008-05-02	Merck Sharp & Dohme Corp.	Somatostatin agonists
JP5564045B2 (ja)	2008-09-02	2014-07-30	ノバルティスアーゲー	二環式キナーゼ阻害剤
GB0818241D0 (en)	2008-10-06	2008-11-12	Cancer Res Technology	Compounds and their use
CA2806332C (en)	2010-07-30	2017-11-14	Oncotherapy Science, Inc.	Quinoline derivatives and melk inhibitors containing the same
RU2637936C2 (ru)	2011-05-23	2017-12-08	Элан Фармасьютикалз, Инк.	Ингибиторы активности киназы lrrk2
US8871756B2 (en)	2011-08-11	2014-10-28	Hoffmann-La Roche Inc.	Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de)	2011-09-14	2013-03-14	Aicuris Gmbh & Co. Kg	Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en)	2011-10-05	2014-08-14	Mapi Pharma Ltd.	Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
WO2014007228A1 (ja) *	2012-07-03	2014-01-09	小野薬品工業株式会社	ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
CN105073729A (zh) *	2012-10-16	2015-11-18	詹森药业有限公司	RORγt的苯基连接的喹啉基调节剂
US9643951B2 (en) *	2013-09-30	2017-05-09	Ono Pharmaceutical Co., Ltd.	Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
JPWO2015146929A1 (ja)	2014-03-24	2017-04-13	武田薬品工業株式会社	複素環化合物
WO2016049568A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Methods and compositions for inhibition of ras
EP3317278B1 (en)	2015-07-01	2021-04-14	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
US9957267B2 (en)	2015-07-01	2018-05-01	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
PT3889145T (pt)	2015-12-17	2024-04-02	Merck Patent Gmbh	8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
MX2019000246A (es)	2016-07-07	2019-05-27	Plantex Ltd	Formas en estado solido del dimesilato de palbociclib.
IL264178B2 (en) *	2016-07-14	2024-05-01	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
PT3740475T (pt)	2018-01-17	2022-07-18	Crinetics Pharmaceuticals Inc	Processo de produção de moduladores da somatostatina
SMT202500155T1 (it)	2018-09-18	2025-05-12	Crinetics Pharmaceuticals Inc	Modulatori della somatostatina e loro usi
JP2022540922A (ja)	2019-07-17	2022-09-20	クリネティックスファーマシューティカルズ，インク．	ソマトスタチンモジュレーターの結晶形態
CA3191084A1 (en)	2020-09-09	2022-03-17	Gerald Burke	Formulations of a somatostatin modulator

2017
- 2017-07-12 IL IL264178A patent/IL264178B2/en unknown
- 2017-07-12 LT LTEPPCT/US2017/041694T patent/LT3484865T/lt unknown
- 2017-07-12 UA UAA201901274A patent/UA125393C2/uk unknown
- 2017-07-12 KR KR1020217035692A patent/KR20210134838A/ko not_active Ceased
- 2017-07-12 NZ NZ750174A patent/NZ750174A/en unknown
- 2017-07-12 US US15/647,758 patent/US9896432B2/en active Active
- 2017-07-12 KR KR1020197004427A patent/KR102324042B1/ko active Active
- 2017-07-12 ES ES17828375T patent/ES2931472T3/es active Active
- 2017-07-12 SG SG11201900349VA patent/SG11201900349VA/en unknown
- 2017-07-12 HU HUE17828375A patent/HUE060182T2/hu unknown
- 2017-07-12 DK DK17828375.0T patent/DK3484865T3/da active
- 2017-07-12 SM SM20220465T patent/SMT202200465T1/it unknown
- 2017-07-12 EP EP22194733.6A patent/EP4163276A1/en not_active Withdrawn
- 2017-07-12 CN CN202211105259.3A patent/CN115557929A/zh active Pending
- 2017-07-12 JP JP2019500810A patent/JP6967577B2/ja active Active
- 2017-07-12 PL PL17828375.0T patent/PL3484865T3/pl unknown
- 2017-07-12 PT PT178283750T patent/PT3484865T/pt unknown
- 2017-07-12 MX MX2019000588A patent/MX390120B/es unknown
- 2017-07-12 HR HRP20221279TT patent/HRP20221279T1/hr unknown
- 2017-07-12 AU AU2017296392A patent/AU2017296392B2/en active Active
- 2017-07-12 RS RS20221103A patent/RS63776B1/sr unknown
- 2017-07-12 EP EP17828375.0A patent/EP3484865B1/en active Active
- 2017-07-12 WO PCT/US2017/041694 patent/WO2018013676A1/en not_active Ceased
- 2017-07-12 CA CA3030423A patent/CA3030423A1/en active Pending
- 2017-07-12 CN CN201780056677.9A patent/CN109715612B/zh active Active
- 2017-07-14 TW TW106123557A patent/TWI789355B/zh active
- 2017-12-20 US US15/849,409 patent/US10351547B2/en active Active
2019
- 2019-01-16 ZA ZA2019/00317A patent/ZA201900317B/en unknown
- 2019-05-08 US US16/407,031 patent/US10597377B2/en active Active
- 2019-12-12 US US16/712,620 patent/US10875839B2/en active Active
2020
- 2020-10-26 US US17/080,358 patent/US11414397B2/en active Active
- 2020-11-24 AU AU2020277122A patent/AU2020277122A1/en not_active Abandoned
2021
- 2021-10-22 JP JP2021173304A patent/JP2022028675A/ja not_active Ceased
2022
- 2022-07-01 US US17/810,497 patent/US20220380337A1/en not_active Abandoned
2025
- 2025-04-25 US US19/189,671 patent/US20260008767A1/en active Pending

Also Published As

Publication number	Publication date
NZ750174A (en)	2023-04-28
IL264178B2 (en)	2024-05-01
AU2017296392A1 (en)	2019-02-28
IL264178A (en)	2019-02-28
US20220380337A1 (en)	2022-12-01
PL3484865T3 (pl)	2023-01-09
PT3484865T (pt)	2022-11-03
US10597377B2 (en)	2020-03-24
TWI789355B (zh)	2023-01-11
US20180016252A1 (en)	2018-01-18
SG11201900349VA (en)	2019-02-27
US20190382367A1 (en)	2019-12-19
CN109715612A (zh)	2019-05-03
CA3030423A1 (en)	2018-01-18
EP3484865B1 (en)	2022-09-14
JP2022028675A (ja)	2022-02-16
DK3484865T3 (da)	2022-10-31
EP3484865A1 (en)	2019-05-22
HRP20221279T1 (hr)	2022-12-23
RS63776B1 (sr)	2022-12-30
ZA201900317B (en)	2022-10-26
TW201805276A (zh)	2018-02-16
UA125393C2 (uk)	2022-03-02
US9896432B2 (en)	2018-02-20
IL264178B1 (en)	2024-01-01
KR102324042B1 (ko)	2021-11-09
BR112019000692A2 (pt)	2019-04-24
EP4163276A1 (en)	2023-04-12
AU2017296392B2 (en)	2020-09-24
MX2019000588A (es)	2019-09-09
US20190002431A1 (en)	2019-01-03
CN115557929A (zh)	2023-01-03
HUE060182T2 (hu)	2023-02-28
EP3484865A4 (en)	2019-12-25
AU2020277122A1 (en)	2020-12-24
ES2931472T3 (es)	2022-12-29
US10351547B2 (en)	2019-07-16
CN109715612B (zh)	2022-09-16
SMT202200465T1 (it)	2023-01-13
JP2019520415A (ja)	2019-07-18
BR112019000692A8 (pt)	2022-03-03
KR20190026914A (ko)	2019-03-13
KR20210134838A (ko)	2021-11-10
US20210171492A1 (en)	2021-06-10
US11414397B2 (en)	2022-08-16
US20260008767A1 (en)	2026-01-08
WO2018013676A1 (en)	2018-01-18
US20200190053A1 (en)	2020-06-18
MX390120B (es)	2025-03-20
US10875839B2 (en)	2020-12-29
JP6967577B2 (ja)	2021-11-17

Publication	Publication Date	Title
LT3484865T (lt)	2022-11-10	Somatostatino moduliatoriai ir jų panaudojimas
FIC20230014I1 (fi)	2023-03-31	Foslevodopa ja foskarbidopa
IL285286A (en)	2021-09-30	Transposase polypeptides and uses thereof
IL248979B (en)	2020-06-30	Syntac polypeptides and uses thereof
FI3494134T3 (fi)	2026-02-19	Muunneltuja polypeptidejä ja niiden käyttötapoja
LT3448386T (lt)	2021-06-25	Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
LT3368534T (lt)	2021-04-12	Valbenazino ditozilatas ir jo polimorfai
LT3317284T (lt)	2020-01-27	Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3212255T3 (da)	2021-03-29	Selvorienterende sprøjte og sprøjtegrænseflade
DK3227342T3 (da)	2019-10-14	Proteinøs heterodimer og anvendelse deraf
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
LT3412302T (lt)	2021-07-26	Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
EP3205103C0 (en)	2024-08-14	INTER AND INTRA UNIFICATION BLOCK COPY
LT3215532T (lt)	2020-01-10	Anti-tim3 antikūnai ir jų naudojimo būdai
EP4135127C0 (en)	2025-11-05	MICRO-ASSEMBLY STRATEGIES AND DEVICES FOR COMPOUNDS
LT3394065T (lt)	2021-06-25	Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
LT3099717T (lt)	2019-09-10	Antikūno molekulės tim-3-čiam ir jų panaudojimas
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3105253T (lt)	2018-09-10	Antikūnai prieš jagged1 ir jų naudojimo būdai
LT3102555T (lt)	2021-06-25	Junginių kompozicijos ir jų panaudojimas
LT3319612T (lt)	2021-08-25	Oksisteroliai ir jų naudojimo būdai
DK3161139T3 (da)	2020-10-19	Tlr-4-specifikke aptamerer og anvendelser heraf
LT3498292T (lt)	2021-11-25	Uspa2 baltymo konstruktai ir jų panaudojimas
LT3672948T (lt)	2022-12-27	Piridinamino-piridono ir pirimidinamino-piridono junginiai